69393-95-9

Usage

Uses

Used in Pharmaceutical Industry:
3,6,9-Trihydroxypterocarpan is used as a pharmaceutical compound for its potential therapeutic effects. Its hydroxy substituents at specific positions allow for interactions with various biological targets, making it a promising candidate for the development of new drugs.
Used in Anticancer Applications:
In the field of oncology, 3,6,9-trihydroxypterocarpan is used as an anticancer agent. It may exhibit inhibitory effects on tumor growth and progression by modulating various oncological signaling pathways, similar to the effects observed with gallotannin. Further research is needed to explore its potential synergistic effects when combined with conventional chemotherapeutic drugs.
Used in Drug Delivery Systems:
To enhance the bioavailability and therapeutic outcomes of 3,6,9-trihydroxypterocarpan, novel drug delivery systems can be developed. These systems may involve the use of organic and metallic nanoparticles as carriers, aiming to improve the compound's delivery to target cancer cells and increase its overall efficacy.

InChI:InChI=1/C15H12O5/c16-8-1-3-10-12(5-8)19-7-15(18)11-4-2-9(17)6-13(11)20-14(10)15/h1-6,14,16-18H,7H2/t14-,15+/m0/s1

Upstream product

• 22532-60-1 2-bromo-4-hydroxybenzaldehyde 

Relevant academic research and scientific papers

Anti-osteoporotic and antioxidant activities of chemical constituents of the aerial parts of Ducrosia ismaelis

A new pterocarpan glycoside, glycinol-3-O-β-d-glucopyranoside (1), and a new dihydrochalcone glycoside, ismaeloside A (2), were isolated together with 13 known compounds, including several flavonoids (3-8), lignans (9-11), and phenolic compounds (12-15), from the methanol extract of the aerial parts of Ducrosia ismaelis. The chemical structures of these compounds were elucidated from spectroscopic data and by comparison of these data with previously published results. The anti-osteoporotic and antioxidant activities of the isolated compounds were assessed using tartrate-resistant acid phosphatase (TRAP), oxygen radical absorbance capacity (ORAC), and reducing capacity assays. Compound 15 exhibited a dose-dependent inhibition of osteoclastic TRAP activity with a TRAP value of 86.05 ± 6.55% of the control at a concentration of 10 μM. Compounds 1, 3-5, and 8 showed potent peroxyl radical-scavenging capacities with ORAC values of 22.79 ± 0.90, 25.57 ± 0.49, 20.41 ± 0.63, 26.55 ± 0.42, and 24.83 ± 0.12 μM Trolox equivalents (TE) at 10 μM, respectively. Only compound 9 was able to significantly reduce Cu(I) with 23.44 μM TE at a concentration of 10 μM. All of the aforementioned compounds were isolated for the first time from a Ducrosia species.

Asymmetric total syntheses of (-)-variabilin and (-)-glycinol

Total syntheses of (-)-variabilin and (-)-glycinol have been accomplished, using the catalytic, asymmetric "interrupted" Feist-Benary reaction (IFB) as the key transformation to introduce both stereogenic centers. A monoquinidine pyrimidinyl ether catalyst affords the IFB products in over 90% ee in both cases. Other key steps include an intramolecular Buchwald-Hartwig coupling and a nickel-catalyzed aryl tosylate reduction.